Leukaemia Trial, Recruiting NCT07131059 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT07131059
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with a specific type of blood cancer called AML (Acute Myeloid Leukaemia), but not the subtype known as APL (M3), as classified under WHO 2016 guidelines
  • People whose disease is in what doctors call a "complete remission" — meaning no leukaemia cells are visible when a bone marrow sample is looked at under a microscope
  • People whose test results still show signs of leukaemia at a very low level (called MRD-positive), detected through specialised bone marrow or blood tests such as flow cytometry, PCR, or gene sequencing looking for specific markers (NPM1, RUNX1-RUNX1T1, CBFB-MYH11, DEK-NUP214, or FLT3)
  • People aged 14 years or older, of any gender
  • People (or their legal guardian or close family member) who are able to sign a consent form before any study procedures begin

Who may not be able to join:

  • People who are planning to have a stem cell transplant within the next 4 weeks
  • People whose diagnosis is APL (the M3 subtype of AML)
  • People whom the research team considers unsuitable for inclusion for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Huui Wei, doctor, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Phone: 13132507161

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
11 May 2024
Est. completion
10 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

relapse-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov